FDA
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on NeuroPace Inc (NPCE) Post NAUTILUS Trial Results
-
-
-
-
-
-
-
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
-
-
-
-
-
-
-
NeuroPace (NPCE) Announces Preliminary Results from One-Year Data in NAUTILUS Study
-
-
-
-
-
-
-
NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy
-
-
-
-
-
-
-
NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
-
-
-
-
-
-
-
NeuroPace Announces Distribution Agreement with DIXI Medical USA, Provider of Intracranial Electrodes and Instruments for Neurosurgery
-
-
-
-
-
-
-
NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

